Barely Significant
← all excerpts

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Sci Rep · 2015 · PMC4671004 · PMID 26639561

Europe PMCDOI
1
hedged sentence
0.0027
closest p · 0.1× alpha
0.0027
boldest claim

The sentences

a clear trendP = 0.0027actually significant
Response When the 57 EGFR -mutant NSCLC patients of the training cohort were grouped as erlotinib responders and non-responders according to BIM mRNA expression, a clear trend emerged: 88.9% of patients with high BIM mRNA expression responded to erlotinib vs 22.2% of patients with low/intermediate BIM levels ( P = 0.0027).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.